New cancer drug DB-1310 enters first human trials

NCT ID NCT05785741

Recruiting now Disease control Sponsor: DualityBio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called DB-1310 in 1000 adults with advanced solid tumors that have worsened after standard treatments. The study aims to find a safe dose and check for early signs of tumor shrinkage. It is a first-in-human study, so the main focus is on safety and tolerability.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DB-1310 (an experimental drug given by IV)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong: This is a very early, first-in-human trial, so safety and effectiveness are not yet known. Many experimental drugs fail in early testing, and side effects may be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm neoplasm non-small cell lung carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Affiliated Hospital of Jiangnan University
RECRUITING

Wuxi, Jiangsu, 214000, China
BRCR Medical Center Inc.
RECRUITING

Tamarac, Florida, 33321, United States
BRCR global
RECRUITING

Plantation, Florida, 33322, United States
Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center
RECRUITING

Cincinnati, Ohio, 45219, United States
D&H Cancer Research Center LLC
WITHDRAWN

Margate, Florida, 33063, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450003, China
Henry Ford Health System
RECRUITING

Detroit, Michigan, 48202, United States
Hunan cancer hospital
RECRUITING

Changsha, Hunan, 410000, China
Jiangsu Province hospital
RECRUITING

Nanjing, Jiangsu, 210000, China
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Research Site 111
RECRUITING

Atlanta, Georgia, 30322, United States
Research Site 117
WITHDRAWN

Coral Gables, Florida, 33146, United States
Research Site 222
RECRUITING

Chengdu, Sichuan, 610041, China
Research site 119
ACTIVE_NOT_RECRUITING

Florham Park, New Jersey, 07932, United States
Sarah Cannon Research Institute at Florida Cancer Specialists
RECRUITING

Orlando, Florida, 32827, United States
Shanghai Chest Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200030, China
Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, 610030, China
Tennessee Oncology, PLLC
RECRUITING

Nashville, Tennessee, 37203, United States
The First Hospital of China Medical University
RECRUITING

Shenyang, Liaoning, 110010, China
The first hospital of Jilin University
RECRUITING

Changchun, Jilin, 130021, China
UCLA Hematology/Oncology - Santa Monica
RECRUITING

Santa Monica, California, 90404, United States
University of California, Davis Comprehensive Cancer Center
RECRUITING

Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.